Candriam S.C.A. Invests $4.01 Million in Abivax SA Sponsored ADR $ABVX

Candriam S.C.A. acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 36,061 shares of the company’s stock, valued at approximately $4,015,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GHP Investment Advisors Inc. lifted its stake in Abivax by 155.6% during the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock valued at $53,000 after purchasing an additional 344 shares in the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in Abivax in the fourth quarter valued at approximately $61,000. WPG Advisers LLC increased its stake in Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after purchasing an additional 253 shares during the last quarter. Finally, Union Bancaire Privee UBP SA acquired a new stake in Abivax during the fourth quarter worth approximately $67,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ABVX shares. Wolfe Research set a $136.00 price objective on shares of Abivax in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Citigroup reaffirmed an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. Citizens Jmp reiterated a “market outperform” rating and set a $187.00 price target on shares of Abivax in a research note on Wednesday, July 1st. Finally, Guggenheim reissued a “buy” rating on shares of Abivax in a research report on Tuesday, June 30th. Fourteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $148.54.

Abivax Stock Down 2.8%

NASDAQ:ABVX opened at $135.98 on Tuesday. The company has a market capitalization of $10.85 billion, a PE ratio of -26.10 and a beta of 0.87. Abivax SA Sponsored ADR has a 52-week low of $8.11 and a 52-week high of $148.83. The stock’s 50 day moving average price is $116.00 and its 200 day moving average price is $118.54.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. As a group, sell-side analysts anticipate that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.